The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats.
about
Traumatic brain injury-induced cognitive and histological deficits are attenuated by delayed and chronic treatment with the 5-HT1A-receptor agonist buspironeA delayed and chronic treatment regimen with the 5-HT1A receptor agonist 8-OH-DPAT after cortical impact injury facilitates motor recovery and acquisition of spatial learningA combined therapeutic regimen of buspirone and environmental enrichment is more efficacious than either alone in enhancing spatial learning in brain-injured pediatric ratsNeither in vivo MRI nor behavioural assessment indicate therapeutic efficacy for a novel 5HT(1A) agonist in rat models of ischaemic stroke.Persistent cognitive dysfunction after traumatic brain injury: A dopamine hypothesisNeuroprotective efficacy of repinotan HCl, a 5-HT1A receptor agonist, in animal models of stroke and traumatic brain injury.Empirical comparison of typical and atypical environmental enrichment paradigms on functional and histological outcome after experimental traumatic brain injury.Evaluation of a combined therapeutic regimen of 8-OH-DPAT and environmental enrichment after experimental traumatic brain injury.Pharmacological interventions for stroke: failures and future.Persistent working memory dysfunction following traumatic brain injury: evidence for a time-dependent mechanism.Abbreviated environmental enrichment enhances neurobehavioral recovery comparably to continuous exposure after traumatic brain injury.Functional recovery of cholinergic basal forebrain neurons under disease conditions: old problems, new solutions?Temporal effects of environmental enrichment-mediated functional improvement after experimental traumatic brain injury in rats.Acute treatment with the 5-HT(1A) receptor agonist 8-OH-DPAT and chronic environmental enrichment confer neurobehavioral benefit after experimental brain trauma.The neurobehavioral benefit conferred by a single systemic administration of 8-OH-DPAT after brain trauma is confined to a narrow therapeutic window.Elucidating the role of 5-HT(1A) and 5-HT(7) receptors on 8-OH-DPAT-induced behavioral recovery after experimental traumatic brain injury.Evaluation of a combined treatment paradigm consisting of environmental enrichment and the 5-HT1A receptor agonist buspirone after experimental traumatic brain injury.Increased striatal serotonin synthesis following cortical resection in children with intractable epilepsyNeurotrophin-mediated neuroprotection of hippocampal neurons following traumatic brain injury is not associated with acute recovery of hippocampal functionAdministration of haloperidol and risperidone after neurobehavioral testing hinders the recovery of traumatic brain injury-induced deficitsImpact of pharmacological treatments on outcome in adult rodents after traumatic brain injury: a meta-analysis.Selective Serotonin Reuptake Inhibitors for Treating Neurocognitive and Neuropsychiatric Disorders Following Traumatic Brain Injury: An Evaluation of Current Evidence.5-hydroxytryptamine1A (5-HT1A) receptor agonists: A decade of empirical evidence supports their use as an efficacious therapeutic strategy for brain trauma.In vitro and in vivo effects of a novel dimeric inhibitor of PSD-95 on excitotoxicity and functional recovery after experimental traumatic brain injury.Galantamine and Environmental Enrichment Enhance Cognitive Recovery after Experimental Traumatic Brain Injury But Do Not Confer Additional Benefits When Combined.NMDA receptor antagonist MK-801 reduces neuronal damage and preserves learning and memory in a rat model of traumatic brain injury.Variants of SLC6A4 in depression risk following severe TBI.Executive (dys)function after traumatic brain injury: special considerations for behavioral pharmacology
P2860
Q24633449-100EEB4B-81AF-40A5-BC85-72681B1DA32BQ24651403-4F8A2381-750A-4A05-AEC7-E7A037B30D7BQ28397908-49F1BA72-5F61-4819-B12B-A04C4BE49C5DQ30870744-C1D76BEB-5561-4723-94B2-1ED04742AC33Q33589580-A5104B35-71E3-4018-A9ED-3E40B461D7FCQ33984607-890D86FE-5FE5-47CA-941E-E12497948A60Q34145744-B3CBBBDD-068F-4B7E-BDF7-5E463E1322FDQ34296853-2BABAD1E-9E05-4702-8014-FF8F062C7D0AQ34628650-8ABEDDC1-5855-4EE7-B0D5-45A9E9A9787AQ34687429-91CC53CD-AD1F-4462-ADD3-39376BC392E8Q34749970-9617EF79-F239-4FD0-9D1F-51BB115E0ED5Q34771671-5AB55AB2-6F5E-4742-A490-639A6B1E027AQ35060994-79CF9F37-E0EC-4F4D-B29A-D569B26EBFBEQ35746505-10436E36-8ADA-49B5-A576-848E6D8EF4B0Q35809500-94E1EC30-BAE1-4B8C-906B-58E7FF37D48AQ35894821-E4E4C422-D43B-4219-88C6-971F5F5566B3Q36079887-FFDAFA1C-FE2C-427B-BC6D-90572D7BF0B3Q36528662-0B635300-FB1B-4F8E-9AEA-B9998F26DF85Q36964156-6F7ECEBE-ABAD-44A4-B432-1875D46B92CAQ37018684-5E91A56E-D1A4-42AF-8363-3063890ECBB9Q37837257-3CEAF0D8-8267-4BC0-BF4F-F3AFDC1141E9Q38649590-44F84B82-5D74-4B7E-BA29-05C6676C89EEQ38650071-423CC90E-FEB2-4D81-8943-FD5A7341BD4DQ38793929-3D92A298-66B3-4072-8CF9-D72005B8E473Q39223215-7D9010B0-FCE6-43A4-AEED-305A28EF3A83Q41350955-3077244C-3F37-4734-9756-86FF864BB432Q44702295-B5670874-645B-4BEF-B1B3-F9C4538106F5Q58739852-57E52CB8-72E6-478B-A228-854F58F7A306
P2860
The selective 5-HT(1A) receptor agonist repinotan HCl attenuates histopathology and spatial learning deficits following traumatic brain injury in rats.
description
2001 nî lūn-bûn
@nan
2001 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2001 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2001年の論文
@ja
2001年論文
@yue
2001年論文
@zh-hant
2001年論文
@zh-hk
2001年論文
@zh-mo
2001年論文
@zh-tw
2001年论文
@wuu
name
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@ast
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@en
type
label
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@ast
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@en
prefLabel
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@ast
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@en
P2093
P1433
P1476
The selective 5-HT(1A) recepto ...... raumatic brain injury in rats.
@en
P2093
P304
P356
10.1016/S0306-4522(01)00300-1
P407
P577
2001-01-01T00:00:00Z